CG Oncology FY2026 Earnings Forecast Lifted by HC Wainwright

CG Oncology, Inc. (NASDAQ:CGON – Free Report) – Investment analysts at HC Wainwright boosted their FY2026 earnings estimates for shares of CG Oncology in a research report issued to clients and investors on Friday, November 6th. HC Wainwright analyst A. Maldonado now forecasts that the company will post earnings of ($2.94) per share for the year, up from their previous forecast of ($3.60). HC Wainwright has a “Buy” rating and a $100.00 price objective on the stock. The consensus estimate for CG Oncology’s current full-year earnings is ($3.03) per share. HC Wainwright also issued estimates for CG Oncology’s Q4 2026 earnings at ($0.70) EPS, Q1 2027 earnings at ($0.85) EPS, Q3 2027 earnings at ($1.02) EPS, FY2027 earnings at ($3.61) EPS, FY2028 earnings at ($1.33) EPS and FY2030 earnings at $5.00 EPS.

A number of other research firms have also recently weighed in on CGON. Royal Bank Of Canada lowered their target price on shares of CG Oncology from $81.00 to $79.00 and set an “outperform” rating on the stock in a research note on Friday, August 7th. Weiss Ratings restated a “sell (d-)” rating on shares of CG Oncology in a research note on Thursday, October 15th. Piper Sandler raised their price target on shares of CG Oncology from $82.00 to $85.00 and gave the stock an “overweight” rating in a research note on Friday, August 7th. Wedbush lifted their price objective on CG Oncology from $80.00 to $84.00 and gave the company an “outperform” rating in a report on Friday, November 6th. Finally, Truist Financial lifted their price objective on CG Oncology from $82.00 to $85.00 and gave the company a “buy” rating in a report on Friday, August 7th. Nine analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $88.11.

Read Our Latest Analysis on CG Oncology

CG Oncology Stock Performance

NASDAQ:CGON opened at $72.61 on Tuesday. The company has a 50-day moving average of $68.13 and a 200-day moving average of $66.36. CG Oncology has a 52 week low of $37.01 and a 52 week high of $80.97. The company has a market capitalization of $6.49 billion, a price-to-earnings ratio of -26.31 and a beta of 0.35.

CG Oncology (NASDAQ:CGON – Get Free Report) last announced its quarterly earnings data on Friday, November 6th. The company reported ($0.64) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.83) by $0.19. The company had revenue of $1.60 million during the quarter, compared to analysts’ expectations of $0.55 million. CG Oncology had a negative net margin of 3,851.09% and a negative return on equity of 24.58%.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Allspring Global Investments Holdings LLC boosted its stake in shares of CG Oncology by 4.9% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 3,728 shares of the company’s stock valued at $255,000 after purchasing an additional 175 shares in the last quarter. Covestor Ltd increased its position in shares of CG Oncology by 72.6% during the 3rd quarter. Covestor Ltd now owns 770 shares of the company’s stock worth $55,000 after purchasing an additional 324 shares in the last quarter. GAMMA Investing LLC lifted its holdings in CG Oncology by 47.9% during the 3rd quarter. GAMMA Investing LLC now owns 1,081 shares of the company’s stock valued at $77,000 after purchasing an additional 350 shares during the last quarter. Fiduciary Financial Advisors bought a new position in CG Oncology during the 2nd quarter valued at about $28,000. Finally, NFSG Corp bought a new position in CG Oncology during the 1st quarter valued at about $34,000. 26.56% of the stock is owned by institutional investors.

Insider Transactions at CG Oncology

In other CG Oncology news, Director Leonard E. Post sold 1,000 shares of the stock in a transaction on Thursday, October 15th. The stock was sold at an average price of $62.06, for a total transaction of $62,060.00. Following the completion of the transaction, the director directly owned 1,000 shares in the company, valued at $62,060. This represents a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders sold 3,000 shares of company stock worth $209,580 in the last three months. Corporate insiders own 4.80% of the company’s stock.

CG Oncology News Roundup

These are some of the CGON news items that stood out recently:

  • Positive Sentiment: CG Oncology’s third-quarter loss was narrower than analysts expected, and revenue exceeded estimates. HC Wainwright also maintained a Buy rating and a $100 price target, raising its FY2026 and Q4 2026 earnings forecasts. What CG Oncology’s Third Quarter Earnings Means For Shareholders
  • Neutral Sentiment: A short-interest update reported zero shares sold short and a zero-day days-to-cover ratio, despite describing short interest as having increased. The figures do not indicate a meaningful short position.
  • Negative Sentiment: HC Wainwright lowered its earnings forecasts for FY2027, FY2028 and FY2030, suggesting it expects a slower path to profitability farther out, although it kept its Buy rating and $100 target.

CG Oncology Company Profile

(Get Free Report)

CG Oncology is a clinical-stage biotechnology company focused on developing treatments for bladder cancer. Based in Irvine, California, the company’s research centers on therapies delivered directly into the bladder. Its lead investigational therapy, cretostimogene grenadenorepvec (formerly CG0070), is an oncolytic immunotherapy being developed for non-muscle-invasive bladder cancer, including disease that has not responded to Bacillus Calmette-Guérin (BCG) treatment. The modified virus is designed to target cancer cells and stimulate an immune response.

Featured Stories

Earnings History and Estimates for CG Oncology (NASDAQ:CGON)

Receive News & Ratings for CG Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CG Oncology and related companies with MarketBeat.com's FREE daily email newsletter.